The BioInsights Podcast
BioInsights
The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.
Episodes
Non-viral methods for ex vivo cell & gene therapy: is the future non-viral?May 31, 2023
Solving challenges in cell therapy clinical trials & effectively delivering complex studies in advanced therapeuticsApril 17, 2023
Shear ignorance? Think again: breaking the perception of shear within viral vector manufacturingApril 06, 2023
Challenges in cryogenic storage containers for cell and gene therapyMarch 22, 2023
Maximizing Efficiency and Flexibility in Viral Vector Manufacturing Scale-upMarch 02, 2023
Improvement of viral vector purification using Mustang Q membrane chromatography December 13, 2022
Shear ignorance? Think again: breaking the perception of shear within viral vector manufacturingNovember 09, 2022
CAR-T cells: from cancer to autoimmunityOctober 12, 2022
Tales, tips & teachable moments from applications support veteransOctober 11, 2022
Access to vaccines: how can we leverage technology innovations to achieve greater vaccine equity?September 30, 2022
De-risk & accelerate the drug development process for gene therapySeptember 29, 2022
Working Together to Safely Advance Cell & Gene TherapiesSeptember 27, 2022
Learning from pediatric CAR-T development: insights from manufacturing unique patient dosesSeptember 26, 2022
Insights into the editing of the human genome: where can novel non-viral polymeric delivery agents take usSeptember 12, 2022
Making the switch from autologous to allogeneic cell therapySeptember 09, 2022
Accelerating cures: funding stem cell innovation & ideas in an evolving cell therapy spaceSeptember 05, 2022
Insights into the editing of the human genome: where can novel non-viral polymeric delivery agents take usAugust 16, 2022
Achieving better AAV vector productivity and product qualityAugust 05, 2022
Partnering in life sciences: what is the ‘secret sauce’ for success? PART 2 July 25, 2022
Partnering in life sciences: what is the secret sauce for success? PART 1: The Big Pharma perspectiveJuly 18, 2022
Where will tomorrow’s workforce come from? PART 4: Who are tomorrow’s cell and gene therapy workers?June 20, 2022
Where will tomorrow’s workforce come from? PART 3: Innovation in staff sourcing, training and retention - what works and what doesn’t?June 20, 2022
Where will tomorrow’s workforce come from? PART 2: How is the educational system responding, and how can the cell and gene therapy community at large help?June 07, 2022
Where will tomorrow’s workforce come from? PART1: Framing the issueJune 07, 2022
The quest for the Holy Grail in AAV chromatography: empty–full separationMay 25, 2022